Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 5/20 | 0.78 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15276898 | 0.92 | SMN1; SMN2 (0.67) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14485108 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL13532179 | 0.87 | LMNA (1.00) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL15276901 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14291713 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL15276892 | 0.83 | MAPT (0.56) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14485232 | 0.82 | MAPT (0.82) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL15276899 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL13532153 | 0.81 | LMNA (0.70) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL28091841 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016310-A1 | METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2008022171-A1 | METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016310-A1 | METHODS OF USING ARYL SULFONYL COMPOUNDS EFFECTIVE AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | SMN1; SMN2 3104/4885LMNA 2362/4885MEN1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.